New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06400472
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first finding a safe dose, then checking if the drug shrinks tumors. About 495 participants will take part over up to 4 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGTokyo, 135-8550, Japan
-
Cancer Research SA
RECRUITINGAdelaide, 5000, Australia
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
HonorHealth
RECRUITINGScottsdale, Arizona, 85258, United States
-
Hospital Clinico Universitario de Valencia
RECRUITINGValencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Humanitas San Pio X
RECRUITINGMilan, 20159, Italy
-
Icon Cancer Centre South Brisbane
RECRUITINGQLD, 4101, Australia
-
Institut de Cancerologie de l'Ouest - site St-Herblain
RECRUITINGSaint-Herblain, 44805, France
-
Istituto Europeo di Oncologia
RECRUITINGMilan, 20141, Italy
-
NYU Langone Health - Long Island
RECRUITINGMineola, New York, 11501, United States
-
National Cancer Center
RECRUITINGGoyang-si Gyeonggi-do, 10408, South Korea
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
New York University (NYU) Clinical Cancer Center
RECRUITINGNew York, New York, 10016, United States
-
Oncopole Claudius Regaud
RECRUITINGToulouse, 31059, France
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Shizuoka Cancer Center
RECRUITINGShizuoka, 411-8777, Japan
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
The Ohio State University (OSU) Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Texas - MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4000, United States
-
University of California, San Diego (UCSD) - Moores Cancer Center
RECRUITINGLa Jolla, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a simple blood test spot ovarian cancer before it starts?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?